Wednesday, June 17, 2009

The truth about Ampligen

Send an Email for free membership
  >>>>> Help ME Circle <<<<
>>>>       30 May 2009        <<<<
Editorship :
mail scanned by Comodo I. Security

The Plot Thickens for HEMISPHERx Biopharma

Written by M.E.Garza

Friday, 29 May 2009 02:01AM

What do we think CFS is?"

Dr. William Reeves asked a worldwide audience
watching his streaming video presentation from the
meeting for the Chronic Fatigue Syndrome Advisory
Committee (CFSAC) of the Department of Health and
Human Services in Washington, DC. on Thursday.

"It's a complex illness, with alterations in complex
homeostatic systems. It's not the result of a single
mutation or a single environmental factor. It
comes from a combination of many factors:
genetics, gender, stressors, immune stressors all

Reeves is chief of the U.S. Centers for Disease
Control and Prevention's Chronic Viral Diseases
Branch, the man in charge of the government's top
Chronic Fatigue Research program.

A few years ago, during a press conference
which was set-up in an attempt to sway
public opinion and policy, Reeves revealed
that CDC researchers had uncovered
groundbreaking, scientific results which
established that CFS had a "biological

It was during that day, in late April of 2006, that
major television networks and hundreds of
newspapers carried the message that many had
been waiting to hear.

In the eyes of advocates and patients, that day
was to forever change the way chronic fatigue
syndrome would be conceptualized - by scientists,
physicians, and the public. At least, that's what
was supposed to happen.

Since that time, Reeves has not minced words
about his science or position on the matter. "CFS is
quite common," Reeves told Forbes Magazine
earlier this year. "It is a real illness. If you have
the symptoms of CFS, see a provider. It's not all in
your head -- it's not a crock."

Yesterday, Reeves was the ring master of what
turned out to be an Ampligen love-in" at the Health
and Human Services event. Not an insignificant fact
when you consider that this was the CFSAC's first
meeting under the Obama Administration's and that
the HHS is at the top of the food chain and rules the
FDA, the CDC, The Social Security Administration,
National Institute of Health, HRSA, Etc.

As some of you may already know, Ampligen, is an
experimental immunomodulatory double stranded
RNA drug developed by HEMISPHERx Biopharma
(Amex: HEB). In addition, it is the only drug in any
pipeline of any pharmaceutical company in the world
which aims to become the standard treatment for

Reeves showed slide after slide with a diagrams and
lists. Almost always near the top of those slides
were references to HEB and Ampligen.

"This is our current model. You see the brain in
the middle. Around the brain, stress is involved,
traumatic childhood stressors, allostatic load
maladaptation to stressors, genes interact with
one's reaction to stress..."

Just then as countless CFS patients and
HEMISPHERx Biopharma investors were
watching, something went "Boom!"

It was yet another grenade lobbed at the publicly
traded company whose stock price had continued
inching upwards for yet another day in anticipation of
the Food and Drug Administration's pending decision
to approve the drug for widespread use in America.

This time, the pin was pulled by Adam Feuerstein, a
graduate from Emory University with a bachelor's
degree in political science who serves as the
Portfolio Manager, Biotech Select for
Adam asserted his own opinion- which apparently
many mistook for scientific fact. "Ampligen will not
be approved."

KABOOM! The moment's Hemispherx's
CFS Drug Is a Long Shot article hit the wires, the
stock's share price started to take a nose dive.

The thinly disguised opinion piece from a writer
without a science or medical degree hit it's mark with
thousands of high-strung investors who began to
dump shares en-masse.

Many thought Feuerstein might just be right, so they
began to sell as quickly as possible. Others thought
the FDA had actually rendered a negative ruling
against the company because the stock was
suddenly dropping in value without any other
apparent explanation. Panic had hit the world of
Hemispherx share holders once again.

Did Feuerstein blister the company on purpose? Was
it all part of a sinister plan orchestrated to sink
prices lower so someone could swoop in and salvage
their piece for a lower price? Whether it was planned
that way or not, at least one big investor did just
that to the tune of over 230,000 shares not long
after HEB parcels had bottomed at $1.51- down from
a day high of $1.76.

Still, it would be expensive, time consuming and
difficult to prove a conspiracy like that beyond
reasonable doubt and we are not here to crucify Mr.
Feuerstein for exercising his constitutionally
protected rights.

Certainly, he's a bright man who is entitled to his
own opinion-- even his conclusions didn't come
wrapped up as nicely as they could have to some
investors who have since taken to slamming him
repeatedly on social media sites and forums across
the web.

Like it or not, this subject has become the talk of
the biomedical financial sector as many feel his
article was not substantiated by enough positive
knowledge or proof. Others argue that his research
was actually filled with misconceptions, and
misplaced scientific information. They're not alone.

Adam Feuerstein wouldn't know good science if it
bit him in the ass!"

In a world where CEOs of publicly traded companies
make it a point not to get into shouting matches
with misled members of the media, I was actually
given explicit permission, told I could "record and
report everything I'm going to say."

"I'm not going to say too much in direct response,
actually. The record can be set straight on this
matter by the government themselves. The same
people who have already told us this is a serious
gene malfunction that costs us north of $90 billion
a year in lost wages and productivity not to
mention social security benefits."

Yes, Dr. William A. Carter, CEO and Chairman of the
Board of HEMISPHERx Biopharma was making it
abundantly clear to me that an exposed nerve had
just been pricked – again. This is the same man who
has been accused of everything from not caring
about his own company's investors to selling snake
oil. He's also the brilliant mind who has never given
up on Ampligen and who genuinely seems driven to
help those who have to live with CFS and the
stigmas associated with it.

It sounds like those guys are living twenty years
behind in time," continued Dr. Carter, as he referred
to Feuerstein's assertion that CFS, a poorly
understood disease with no known cause..."

Had Feuerstein really not gotten the memo about the
scientific community's findings in 2006 or did he
simply choose to ignore them?

This is a disease that destroys lives," said
an impassioned Dr. Carter. "It costs people
their jobs, their marriages- as their
frustrated spouses walk out on them. In
some cases it even costs them their very
lives due to suicide and catastrophic heart
failure. Our drug helps so many of these
very sick, suffering people. There is ample
peer reviewed data and proof of that, yet
they choose to ignore it.

Perhaps the writers at are unaware
that for several years now, the FDA has given people
suffering with CFS the right to use Ampligen for
emergency (compassionate) use.

Indeed, the company is authorized by the FDA and
has a "promising'' designation by the Agency on
Health Research Quality (AHRQ) emergency
treatment, which means HEMISPHERx can charge
patients up to $20K a year for treatments.

"That's a price most health insurance companies
actually prefer to pay when compared to the high
costs of misdiagnosis, MRIs, CAT scans and even
surgeries that occur from time to time when patients
suffering from the illness show up at hospital
emergency rooms seeking help," explained Dr.

"In order for us to get that designation, the
government had to establish that CFS was,
indeed, a very serious disease. Second, the FDA
had to be shown that there was not any other
adequate treatment and perhaps most
importantly, Ampligen had to be safe to
administer. That is one thing that has never been
withdrawn or questioned by them.

In fact, one insider tells us that in the early days of it's use under the program, the FDA required the company to submit safety reports every month. They did so every month for 150 months. In fact, the reports were delivered with such positive data and accuracy that eventually a top administrator at federal agency grew tired of reading them. He told them to stop.

The CDC, as represented during Thursday's
presentation, has made important commitments to
HEMISPHERx when I comes to CFS.

"We're talking to them two to three times a week
as we compare protocols and treatments,"
explains Dr. Carter. "Because they have vast
resources, they have been prolific in the
publication of research about the disease. They've
published about the severity of the gene
malfunction. This is a major medical research
organization in the world and they recognize that
we are leaders in the field of CFS.

You can't tell me they're not aware of that... I don't
know what the agenda is at TheStreet.Com, but
those guys may as well start selling off their 401K's
because they apparently know very little about
investing. Not only do they manipulate the facts-
they conspicuously don't talk about our
collaborations and data.

The same drug used for CFS has now taken center
stage in the fight against so called swine flu (H1N1).
The company has made headlines in recent days as
it has moved full force into collaboration with health
ministries and scientists in Japan. In fact,
BiomedReports has learned that the company is
officially on the fast ...


Anonymous said...

Why are you stealing this content from BioMedReports.Com without giving credit or a link?

CFS Facts said...

It is posted EXACTLY as I received it from someone else, with a link of, which was in the original which I received.

If there is some other link that should be attached, please advise what that is. I can only post what I receive; I have no idea where they got it other than the link they include.

Credit *is* given to the author, Garza.